Close Menu

Waters

Instruments sales were down 8 percent, but its Acquity UPLC system continued to gain traction in the market, and its recently launched Synapt G2 is receiving as strong a reception as any instrument launched by Waters in recent years, company officials said.

Waters' revenues declined 9 percent year over year, while its adjusted EPS missed analysts' consensus estimate by a penny.

Despite the gyrations on Wall Street, the stocks of the largest mass spectrometer manufacturers rose an average of almost 48 percent for the first half of 2009, according to ProteoMonitor's sister publication GenomeWeb Daily News.

In a research note, Isaac Ro of Leerink Swann noted that Waters pioneered the UHPLC category with the Acquity "and has a considerable leadership position, a large installed base, and a wide menu of proprietary columns."

Leerink Swann upped its revenue estimates for 2009 and stock valuations for both firms.

Sustained interest in its high-end mass specs as well as the Acquity UPLC, along with stimulus-fund spending, fueled cautious optimism from CEO Douglas Berthiaume that the worst may have passed.

Waters shares rose sharply on tuesday afternoon after the firm's earnings per share for the first quarter handily beat Wall St. estimates. The firm's Q1 revenues, however, were down 10 percent year over year.

Pages

Holden Thorp is to be the new editor-in-chief of Science and its related journals.

A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.

Adelaide University has suspended the head of an ancient DNA lab as its investigation of workplace bullying continues, Australia's ABC News reports.

In PNAS this week: gene expression profiles of adipocyte subtypes, computational approach for improving plant expressome analysis, and more.